March 18, 2015 — A 22 year-old man who was prescribed Risperdal as a child and developed gynecomastia has been awarded $2.5 million by a jury in Philadelphia, according to Philly.com.
The lawsuit was filed on behalf of a man from Alabama who was prescribed Risperdal “off-label” in 2002, when he was just eight years old. He soon developed gynecomastia, a condition that caused him to grow size 46DD breasts.
It was not until 2006 that the FDA approved Risperdal for the treatment of irritability associated with certain intellectual disabilities. However, the Justice Department accused Johnson & Johnson of targeting child psychiatrists and engaging in illegal “off-label” marketing. In 2013, the drug-maker agreed to pay $2.2 billion to resolve civil and criminal allegations.
His pediatric neurologist was visited by sales representatives marketing Risperdal on at least 20 occasions. His doctor testified that he was not aware of the link between Risperdal and gynecomastia. Had he known, he would have warned his family.
Meanwhile, a number of states have ordered Johnson & Johnson to pay hundreds of millions of dollars for improperly marketing Risperdal while failing to warn about side effects. Reuters reports that South Carolina’s Supreme Court slashed a $327 million judgement down to $136 million, citing state laws regarding statute of limitations.
Do I have a Risperdal Lawsuit?
The Schmidt Firm, PLLC is currently accepting Risperdal induced injury cases in all 50 states. If you or somebody you know has been diagnosed with gynecomastia, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.
Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.